SCHEMBL5382919

SCHEMBL5382919

CN(C)S(=O)(=O)NCC1CCC(N)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
NPY5R Q15761 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
GBA1 P04062 1/20 0.36
SMYD3 Q9H7B4 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CYP2C9 P11712 1/20 0.31
JAK2 O60674 2/20 0.31
JAK1 P23458 2/20 0.31
HTR6 P50406 1/20 0.31
ADRA2A P08913 1/20 0.31
TYK2 P29597 1/20 0.30
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3918722 0.90 ALDH1A1 (0.45) ALDH1A1NPY5RMEN1KMT2APOLB
SCHEMBL5131843 0.85 ALDH1A1 (0.38) ALDH1A1NPY5RMEN1KMT2APOLB
SCHEMBL5382485 0.80 TDP1 (0.43) ALDH1A1NPY5RMEN1KMT2APOLB
SCHEMBL1542985 0.79 GBA1 (0.39) ALDH1A1NPY5RMEN1KMT2AGBA1
SCHEMBL13240743 0.79 GBA1 (0.39) ALDH1A1NPY5RMEN1KMT2AGBA1
SCHEMBL12313412 0.77 NPY5R (0.41) ALDH1A1NPY5RMEN1KMT2APOLB
SCHEMBL11934709 0.77 GBA1 (0.38) ALDH1A1NPY5RMEN1KMT2AGBA1
SCHEMBL14012774 0.77 GBA1 (0.38) ALDH1A1NPY5RMEN1KMT2AGBA1
SCHEMBL17723322 0.76 CA2 (0.43) GBA1TDP1CA1CA2
SCHEMBL5387500 0.76 NPY5R (0.42) ALDH1A1NPY5RMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273880-B2 Selective NPY (Y5) antagonists H. LUNBECK A/S (DK) 2007-09-25 US disclosed
EP-1194421-B1 SELECTIVE NPY (Y5) ANTAGONISTS LUNDBECK & CO AS H (DK) 2005-10-12 EP disclosed
US-20050137240-A1 Selective NPY (Y5) antagonists H. LUNDBECK A/S (DK) 2005-06-23 US disclosed
EP-1194421-A4 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2002-09-11 EP disclosed
EP-1194421-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2002-04-10 EP disclosed
US-6225330-B1 Selective NPY (Y5) antagonists (tricyclics) SYNAPTIC PHARMACEUTICAL CORPORATION 2001-05-01 US disclosed
WO-2001002379-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137240-A1 Selective NPY (Y5) antagonists NPY5R, NPY1R, NPY2R ALDH1A1 4658/4885NPY5R 1/4885MEN1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.